tiprankstipranks
Advertisement
Advertisement
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
PremiumRatingsInsight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
25d ago
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Premium
Company Announcements
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
28d ago
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
Premium
The Fly
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
1M ago
Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
PremiumThe FlyInsight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
3M ago
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
Premium
Ratings
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
3M ago
iMDx prepares for U.S. commercial launch of GraftAssureDx
Premium
The Fly
iMDx prepares for U.S. commercial launch of GraftAssureDx
3M ago
Insight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year
PremiumThe FlyInsight Molecular Diagnostics reports Q3 EPS (34c) vs. (98c) last year
5M ago
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study
Premium
Company Announcements
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study
5M ago
Insight Molecular says kidney transplant patient achieved ‘immune reset’
Premium
The Fly
Insight Molecular says kidney transplant patient achieved ‘immune reset’
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100